KQB368 as a single-drug treatment for adults with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, interventional study to evaluate KQB368 as a monotherapy in adults with advanced solid malignancies, including colorectal cancer, non-small cell lung cancer, uterine cancer, and cancers with KRAS G12C or G12S mutations. The primary goals are to determine a safe starting dose, observe changes in tumor size, and understand how the drug is processed by the body. Participants will take KQB368 orally in 21-day cycles and visit the clinic regularly during the first 5 weeks, then at the start of each subsequent cycle. The study will monitor safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity using RECIST v1.1 criteria.

Why it matters

Who can join: the full rules

* Histologically confirmed diagnosis of a solid tumor
* Malignancy with either a KRAS G12C or KRAS G12S mutation
* Unresectable or metastatic disease
* No available treatment with curative intent
* Adequate organ function
* Measurable disease per RECIST v1.1
* Must be able to swallow with no GI condition that prevents absorption

Where it's running

• START Los Angeles
  Los Angeles, California, United States Recruiting
• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting
• Karmanos Cancer Institute
  Detroit, Michigan, United States Recruiting
• John Theurer Cancer Center at Hackensack UMC
  Hackensack, New Jersey, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting
• UH Cleveland Medical Center
  Cleveland, Ohio, United States Recruiting

Study contacts

• Study coordinator: Kumquat Clinical Development Telephone
• Email: kumquatstudies@kumquatbio.com
• Phone: 858.214.2700

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• FL-261 imaging to detect and stage c-MET–expressing cancers

  This first-in-human test uses FL-261 labeled for PET or SPECT to see if it safely highlights c-MET–positive tumors in adults with advanced solid tumors such as non-small cell lung, colorectal, or head and neck cancer.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07510321

• First-in-human test of CKD-703 for advanced solid tumors and non-small cell lung cancer

  This trial will test CKD-703, a targeted antibody–drug conjugate, in adults with advanced c‑Met–expressing solid tumors and in MET‑amplified or c‑Met–overexpressing non‑small cell lung cancer who have exhausted standard treatments.

  Recruiting Phase 1/2 Chong Kun Dang Pharmaceutical · Ohio City, Ohio · NCT07439094

• BPI-572270 in RAS-mutant advanced solid tumors (including NSCLC, CRC, PDAC)

  This study tests whether BPI-572270 is safe and tolerable in adults with RAS-mutant advanced solid tumors and looks for signs of clinical activity.

  Recruiting Phase 1/2 Betta Pharmaceuticals Co., Ltd. · Blacktown, New South Wales and 6 other locations · NCT07435038

• Combining RAS(ON) inhibitors with ivonescimab for adults with RAS‑mutant advanced solid tumors

  This trial will test whether combining RAS(ON) inhibitors with ivonescimab is safe and can shrink or control tumors in adults with advanced or metastatic solid tumors that have RAS mutations.

  Recruiting at 19 sites Phase 1/2 Revolution Medicines, Inc. · Scottsdale, Arizona and 18 other locations · NCT07397338

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.